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Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): A Single Institutional Review with Emphasis on Tumor Prevalence
Nabil Ashraf, Rongqin Ren, Cora Uram-Tuculescu, Celeste N Powers, Adele O Kraft. Virginia Commonwealth University Health System, Richmond, VA. Background: Noninvasive encapsulated follicular variant of papillary thyroid carcinoma (NIFTP) is a recently proposed designation for a subset of follicular variant of papillary thyroid carcinoma (FVPTC) cases defined by strict histopathological criteria and with an indolent biologic behavior when compared to invasive FVPTC. Given the currently limited published data and in an effort to assess NIFTP prevalence and tumor characteristics a retrospective review of FVPTC cases was performed at our institution. Design: A computerized search of all cases of papillary thyroid carcinomas (PTC) from 2006 to 2016 was performed at our institution. FVPTC cases with reported capsular and/or angiolymphatic invasion, metastatic and/or recurrent tumors were excluded. Slides from the remaining FVPTC cases were examined by four pathologists to assess the published NIFTP major and minor inclusion and exclusion criteria for possible re-classification. Tumor characteristics including size, focality, encapsulation, and background thyroid abnormalities as well as additional clinical parameters and outcomes were noted. Results: A total of 218 thyroidectomy specimens with primary, nonmetastatic PTC, were identified. Of these 73 were diagnosed as FVPTC and 42 were excluded due to reported capsular and/or angiolymphatic invasion. After review 17 cases of the remaining 31, met the published criteria for NIFTP. All the15 NIFTP patients with available follow up information were disease-free (range: 2 months to 9 years, mean 2.7 years).
Cases
Number (%) Reasons for exclusion* Number of cases
Infiltrative borders 10
True papillae > 1% 10
Lack of encapsulation or demarcation 5
Psammomma bodies 4
Tumor Necrosis 0
High mitotic activity 0 Nuclear score < 2 0
Features of other PTC variants 0 *Some potential NIFTP cases failed multiple criteria Conclusions: At our institution 8% of primary, nonmetastatic PTC cases identified on thyroidectomies met the proposed published criteria for the NIFTP category.
1289
Pleomorphic Adenoma: Benign, Recurrent and Malignant Transformation Munita Bal, Swati Thorat, Swapnil Rane, Asawari Patil, Shubhada Kane, Rajiv Kumar, Gouri Pantavaidya, Jai Prakash Agarwal, Anil DCruz. Tata Memorial Centre, Mumbai, Maharashtra, India. Background: Pleomorphic adenoma (PA) is an enigmatic tumor with unique pathological features and an unpredictable tendency towards malignant transformation in a subset of cases. Our aim was to study the clinicopathologic spectrum of benign, recurrent and malignant PA diagnosed at our centre. Design: A retrospective review of clinical and pathologic findings of head and neck PA cases diagnosed from 2004-2013 was undertaken. Results: 187 PA cases were studied and subdivided into 3 groups (G): G1, non-recurrent PA (n=94); G2, recurrent PA (n=23); and G3, PA with malignant transformation (PAMT) (n=70). Median time-to-recurrence and time-to-malignant transformation was 6.5 years and 19 years in G2 and G3 cohorts, respectively. G2 cases had an earlier median age of onset, male predominance, larger mean tumor size, stroma-rich histology and greater cellular atypia, mitotic rate, satellite nodules and extra-parenchymal spread (EPS) than G1 cases. Among G3, 46 cases were de novo (PAMT at first presentation) while 24 were secondary (following a previously documented/resected PA); commonest histology was salivary duct carcinoma and myoepithelial carcinoma in de novo and secondary groups, respectively. Larger size, higher T stage, increased margin positivity and shorter disease free survival was seen in secondary versus de novo tumors. High T stage, EPS, high grade, margin positivity and nodal metastasis was seen in 91%, 89%, 80%, 28% and 39% G3 cases, respectively. Intracapsular carcinoma and minimally-invasive PAMT (i.e. extracapsular invasion ≤ 1.5 mm) were associated with favorable prognosis when compared to widely-invasive PAMT (p value=0.02) . Conclusions: PA is a unique clinicopathologic entity. Recurrent PA exhibit atypical pathological features. PAMT display a wide pathologic spectrum, aggressive clinicopathologic features and a poor prognosis. Intracapsular and minimally-invasive PAMTs are a favorable prognostic category among the malignant PA cohort. Diana Bell, Shirley Y Su, Bonnie Glisson, Merril Kies, Victor G Prieto, Renata Ferrarrotto. MD Anderson Cancer Center, Houston, TX. Background: Merkel cell carcinoma (MCC) is an aggressive high-grade neuroendocrine skin tumor frequently associated with the Merkel cell Polyomavirus (MCPyV). The genetic landscape of MCPyV negative tumors mirrors small cell lung cancer (SmCC), majority harboring mutations in TP53 and RB1 and scarce actionable mutations in oncogenes. Patients with recurrent/ metastatic disease are treated with similar SmCC chemotherapy schemas. Based on profiling data of SmCC revealing a high expression of DNA repair proteins, particularly PARP1, and promising anti-tumor activity of PARP inhibitors in SmCC patients in early clinical trials, we aimed to evaluate the expression of PARP1 in MCC. Design: A cohort of 19 patients diagnosed with MCC and with tissue available for histological studies was identified. IHC analysis for PARP1 was performed in 4 micron paraffin embedded tissue sections; only tumor tissue with strong nuclear staining in > 10% of the neoplastic cells were considered positive. Polyoma virus status was evaluated by staining with anti-MCPyV antibody in the tissue specimens. Patient's characteristics were collected retrospectively.
PARP1 Overexpression in Merkel Cell Carcinoma and Its Potential Clinical Implications
Results:
The median age at diagnosis was 71 years old, 74% (14/19) of patients were male, 74% (14/19) had a primary tumor in the head and neck region. PARP1 and MCPyV expression 42% tumors (8/19) were MCPyU positive. Strong PARP1 IHC staining was observed in the majority of cases (15/19 or 79%).
A, B-H&E of Merkel cell carcinoma of eyelid. C-Phenotypically the tumor display characteristical perinuclear pattern when stained with anti-CK20 antibody. Diffuse strong nuclear positivity with anti-PARP1 (D) and MCPyV (E) antibodies). There was no statistical correlation between PARP1 overexpression and MCPyU status or primary site of disease. Conclusions: As observed in small cell lung cancer, PARP1 overexpression is prevalent in MCC suggesting underlying defects in DNA-repair in this tumor type. MCC represents a major unmet need that poses the additional challenging of affecting preferentially immunosuppressed individuals, limiting the use of the emerging immunotherapy option. Given the early signs of activity of PARP inhibitors in SCLC, we believe this class of agents deserves further investigation in MCC patients. All cases demonstrated prominent clear cell morphology and serous acinar differentiation ( figure 1A ). PAS-D (3/3), SOX-10 (4/4) (figure 1B), and DOG1 (5/5) ( figure 1C ) were positive in all tested cases. MAML2 FISH was positive in all cases (figure 1D), in both acinar and mucoepidermoid components. Two cases tested by next generation sequencing showed standard CRTC1-MAML2 fusions.
Conclusions: MEC with acinar differentiation or "mucoacinar" carcinomas represent a "distal" acinar variant morphology in MEC, rather than a distinct entity or collision tumor. The acinar differentiation and SOX-10/DOG-1 reactivity may thus be a diagnostic pitfall.
1295
Identification of Novel Gene Fusion EWSR1-CREM in Hyalinizing Clear Cell Carcinoma (HCCC) by Anchored Multiplex Polymerase Chain Reaction
Erin Chapman, Angela Goytain, Malcolm Hayes, Wei Xiong, Alena Skalova, Josh Haimes, Brian Kudlow, Cheng-Han Lee, Tony Ng. Vancouver General Hospital, Vancouver, BC, Canada; B. C. Cancer Agency, Vancouver, BC, Canada; St. Paul's Hospital, Vancouver, BC, Canada; Charles University, Pilsen, Czech Republic; ArcherDx, Inc., Boulder, CO; University of British Columbia, Vancouver, BC, Canada. Background: EWSR1-CREB-family gene fusions are described in diverse neoplasms, including the characteristic EWSR1-ATF1 fusion in HCCC. Anchored multiplex polymerase chain reaction (AMP) is a next-generation sequencing-based technique in which novel gene fusions can be identified following PCR-based amplification that targets a panel of genes commonly involved in oncogenic fusions; one set of primers target one partner gene, while the other partner is identified through next-generation sequencing agnostic to the identity of the other partner. We describe a novel gene fusion, EWSR1-CREM, identified in a case of HCCC using AMP. Design: The patient was a 68 year old female with a base of tongue mass. Clear cell morphology, presence of mucin, and the immunoprofile raised a differential diagnosis of HCCC versus a mucoepidermoid carcinoma. EWSR1 and ATF1 FISH were performed during the initial diagnostic work-up. AMP was performed on this case with the goal of identifying the hidden fusion partner (Archer(R) Sarcoma FusionPlex(R) kit). Further testing included RT-PCR. Results: Initial FISH showed the presence of an EWSR1 rearrangement but absence of an ATF1 rearrangement. AMP demonstrated a novel EWSR1-CREM fusion, with the fusion junction between EWSR1 exon 13 and CREM exon 5. This finding is biologically justified as CREM is a recognized paralog of ATF1, with both belonging to the CREB family of transcription factors.
Conclusions:
We describe a case of HCCC demonstrating that CREM can replace ATF1 as the EWSR1 fusion partner. EWSR1-CREM fusions have not been previously reported in HCCC and have only rarely been reported in other tumours. We also show that a targeted next-generation sequencing-based assay such as AMP has the capability of discovering novel or unexpected fusion gene variants, and has clinical utility in the pathological classification of fusion gene-associated tumors with variable partner genes. Yoon Ah Cho, Ji Myung Chung, Eun Kyung Kim, Su Jin Heo, Byoung Chul Cho, Hye Ryun Kim, Sun Och Yoon. Yonsei University College of Medicine, Seoul, Republic of Korea. Background: Treatment of head and neck squamous cell carcinomas (HNSCC) are challenging due to loco-regional recurrences and metastasis. Previous studies revealed that Tropomyosin-related kinase B (TrkB) is overexpressed in HNSCC. However, the relationship between HNSCC and subtypes of Trk proteins is not robustly studied. In this study, we try to evaluate expression of all subtypes of Trk proteins and its clinicpathological significance. Design: A total of 396 radically resected HNSCC cases were used for tissue microarray construction. Immunohistochemistry was performed for TrkA, TrkB, pan-Trk (TrkA+B+C) and evaluated through H-score analysis (0-300 scale). The cutoff for high Trk expression was determined at the mean value of H-scores. Results: Oropharyngeal SCC revealed relatively higher expression of pan-Trk and TrkA (P<0.05). Expression of pan-Trk and TrkA was higher in p16-positive HNSCC than p16-negative cases (P<0.001). Expression of pan-Trk was higher in HNSCCs with lymphovascular invasion (P<0.001) , perineural invasion (P=0.023), more advanced pT (P<0.001), and more advanced pN stage (P<0.001) than cases without such factors. In patients of completely resected (R0 resection) oropharyngeal SCC, high TrkA expression was related to superior overall survival rate (P=0.044). In patients of oral cavity SCC with R0 resection, high pan-Trk was related to inferior overall survival rate (P<0.001). TrkB expression revealed no association with variable clinico-pathologic factors or patient prognosis. Conclusions: Expression pattern of pan-Trk and TrkA was different according to anatomical sites and HPV infection status. High expression of pan-Trk may be related to poor prognosis, especially in oral cavity SCC while high TrkA expression may be related to favorable prognosis, especially in oropharyngeal SCC. Although further evaluation about implications of TrkC is necessary, Trk expression should be considered in the context of anatomical sites and each Trk subtype.
Expression Pattern of Trk Proteins in Head and Neck Squamous Carcinoma and Its Prognostic Significance
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Comprehensive Genomic Profiling of Salivary Gland Myoepithelial Carcinoma Siddhartha Dalvi, Julia A Elvin, Jo-Anne Vergilio, James Suh, Shakti H Ramkissoon, Kai Wang, Daniel Bowles, Hilary Somerset, Siraj M Ali, Alexa Schrock, David Fabrizio, Garrett Frampton, Vincent Miller, Philip Stephens, Laurie M Gay, Jeffrey Ross. Albany Med Col, Albany, NY; Foundation Med, Boston, MA; Univers of Colorado, Denver, CO. Background: Myoepithelial carcinomas (MyC) of salivary glands (SG) are typically low-grade malignancies that can arise de novo or in the background of a pre-existing pleomorphic adenoma (CPA). On occasion, MyC can present or progress into locoregionally advanced and/or metastatic disease. Design: DNA was extracted from 40 uµ of FFPE sections from 24 relapsed and metastatic MyC. Comprehensive genomic profiling (CGP) was performed using a hybrid-capture, adaptor ligation based next generation sequencing assay to a mean coverage depth of >712X. Tumor mutational burden (TMB) was calculated from a minimum of 1.11 Mb of sequenced DNA and reported as mutations/Mb. The results were analyzed for all classes of genomic alterations (GA), including base substitutions (sub), insertions and deletions (short variants), fusions, and copy number changes including amplifications (amp) and homozygous deletions. Results: 21 (87.5%) of MyC arose de novo and 3 (12.5%) presented as carcinoma ex pleomorphic adenoma. 14 (58%) MyC patients were male and 10 (42%) female with a mean age of 61.3 years (range 26 to 83 years). 4 (18%), 6 (25%) and 14 (58%)MyC were well, moderately and poorly differentiated. At the time of CGP, 10 (42%) MyC were stage III and 14 (58%) were stage IV. Sequencing was performed on the primary and metastatic sample in an equal number of cases (12 each). Of 22 cases where the primary site was known 16 (73%) arose in the parotid SG, 1 (5%) in the submandibular SG and 5 (22%) from accessory SG. The 24 MyC featured 2.3 GA/case with the most frequent clinically relevant GA (CRGA) involving RICTOR amp and PIK3CA sub (13%); PTCH1 and PDGFRB sub (8% each) and NF1 and BRCA2 sub (4% each). There were no ERBB2 GA. The most frequent non-actionable GA were CDKN2A loss (25%), CDKN2B loss and HRAS sub (21% each), TERT, MYC, TP53 and NOTCH1 subs (13% each).2 (8%) MyC featured TMB > 20 mut/Mb and 22 (92%) featured TMB < 10 mut/ Mb. No MyC cases had MSI-high status. Conclusions: Clinically advanced MyC are similar to the usually less aggressive SG tumors, adenoid cystic and acinic cell carcinomas in having low GA/tumor, low TP53 mutation frequency, low TMB and general paucity of CRGA when compared to the usually more aggressive adenocarcinomas which may feature alterations in ERBB2 and other pathways. However, the findings of CRGA in RICTOR, PTCH1, NF1 and BRCA2 and the presence of high TMB in a subset of MyC cases encourages continued use of CGP to search for targeted and immunotherapies for this rare type of progressive head and neck cancer.
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Genomic Profiling of the Two Closely Related "cousins" Acinic Cell Carcinoma and Mammary Analog Secretory Carcinoma of Salivary Glands Reveals Novel NCOA4-RET Fusion in Mammary Analog Secretory Carcinoma Snjezana Dogan, Ryma Benayed, Hui Chen, Maria E Arcila, Michael F Berger, Nora Katabi. Memorial Sloan Kettering Cancer Center, New York, NY. Background: Acinic cell carcinoma (AciCC) is a rare malignant salivary gland neoplasm that is genetically largely undefined. Mammary analog secretory carcinoma (MASC), a recently described entity previously classified as AciCC is characterized by ETV6-NTRK3 fusion. However, a minor proportion of tumors morphologically compatible with MASC are negative for ETV6 rearrangement suggesting the presence of other driver genetic alterations. Here, we used a broad genomic analysis to examine the differences between the two morphologically close tumor entities. Design: Genomic profiling was performed on 22 tumors including 15 (68.2%) AciCCs, 6 MASCs (27.3%), and one (4.5%) high grade carcinoma with features of both, AciCC and MASC (AciCC/MASC (2015) (2016) were stained using RNA ISH to detect high-risk HPV E6-E7 mRNA and compared to p16 IHC (Ventana RTU). The RNA ISH used the RNAscope (Leica BioSystems, Buffalo Grove, IL), the Bond III autostainer (Leica), and RNAscope® 2.5 LS Probe -HPV-HR18 (high risk pool of 18 individual HPV probes: HPV 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82; Advanced Cell Diagnostics, Newark, CA) , as well as a negative (Dap B) and positive probe (PP1B for RNA). Two pathologists reviewed and graded the RNA ISH stainedslides and reached a consensus on all interpretations. Results: RNAscope HPV test detected 100% (21/21) of the p16 IHC positive samples. It detected 50% of the p16 IHC negative samples (3/6). These three RNA ISH positive samples had rare positivity, read as <5%. All other positive samples had >10% positivity. All of the RNA ISH negative samples were p16 IHC negative (3/3 Design: EMCAs (n=39) were reviewed for morphologic evidence of PA. High grade transformation (HGT) was defined by the presence of necrosis. PLAG1 and HMGA2 alterations were detected by fluorescence in situ hybridization (FISH). EMCAs with intact PLAG1 and HMGA2 (n=11) were tested for other fusions, including fibroblast growth factor receptor 1 (FGFR1)-PLAG1, as previously described (PMID: 26747586). Twenty-three tumors were also analyzed for mutations and copy number variations in 50 cancer-related genes (PMID: 27379604). Results: Based on combined morphologic and molecular evidence of PA, 4 subsets of EMCA emerged: 1) carcinomas with morphologic evidence of PA but intact PLAG1 and HMGA2 (n=10); 2) carcinomas with PLAG1 fusion (n=9); 3) HMGA2 alteration (n=9, including 3 cases without morphologic evidence of PA); and 4) de novo carcinomas, without morphologic or molecular evidence of PA (n=11). Two cases with intrachromosomal FGFR1-PLAG1 fusion were identified by RNA fusion panel only (PLAG1 FISH was negative). Disease-free survival and clinicopathologic parameters did not differ for the subsets defined above. The relationship between the 4 subgroups, presence of HGT, and molecular findings are summarized in Figure 1 .
HRAS (5 of 7 vs 3 of 16 tumors; p=0.01) and TP53 alteration (3 of 7 vs 0 of 16 tumors; p<0.01) were observed predominantly in de novo carcinomas. Conclusions: Most EMCAs are ex PA (28/39, 72%). The genetic profile of EMCAs varies with the absence or presence of pre-existing PA and its molecular signature. PLAG1 FISH underestimates the prevalence of FGFR1-PLAG1 fusion by 18% (2/11). The de novo EMCAs more commonly harbor HRAS, TP53, and/or FBXW7 alterations.
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Melan-A Expression in Olfactory Neuroblastoma Amelia Fierro-Fine, Robert Robinson, Anthony Snow. University of Iowa, Iowa City, IA. Background: Olfactory neuroblastoma is a rare tumor of the sinonasal tract of neuroectodermal origin representing nearly 6% of nasal and paranasal sinus tumors. The cell of origin is thought to be a reserve neuroepithelial cell of the sinonasal tract with neuro-endocrine capabilities including production of neurosecretory granules. Some olfactory neuroblastomas have melanin or a melanin-like pigment which may confound the diagnosis with sinonasal melanoma. Our group encountered a small biopsy which showed few distinguishing morphologic features and strong positivity for Melan-A (MART-1) that ultimately proved to be an olfactory neuroblastoma. No significant literature documenting Melan-A positivity in olfactory neuroblastoma was available for comparison. Melan-A IHC is examined in olfactory neuroblastoma to determine its usefulness in distinguishing olfactory neuroblastoma from sinonasal melanoma or to provide evidence to avoid its use.
Design: Formalin fixed paraffin embedded olfactory neuroblastoma specimens from 25 patients were identified from our case files between 1997 and 2015. The FFPE blocks were stained with anti-human Melan-A monoclonal mouse antibody (Dako, Clone A103) at a 1:25 dilution, and the staining strength and pattern were evaluated by two pathologists. Results: 4 of 25 olfactory neuroblastomas showed diffuse weak (1+) cytoplasmic immunohistochemical positivity for Melan-A while 2 cases showed moderate (2+) patchy cytoplasmic staining, 1 case showed diffuse strong (3+) cytoplasmic staining, and 1 case (the index case) showed diffuse strong (3+) cytoplasmic staining and nuclear signal. Conclusions: 28% of cases of olfactory neuroblastoma demonstrated immunohistochemical positivity for Melan-A. All showed either diffuse and/or strong signal. It has not been determined whether the signal is from Melan-A produced by the tumor, or cross reactivity with similar steroid epitopes in some olfactory neuroblastomas. Cross reactivity is favored as the character of cytoplasmic staining is finer than that commonly observed in melanoma and nuclear signal was observed in some cases. Similar examples of probable cross reactivity have been established in adrenocortical tumors, granulosa cell tumors, and leydig cell tumors particularly with clone A103. Interpretation of Melan-A positivity should be approached with caution in the context of small biopsies from the sinonasal mucosa in which melanoma and olfactory neuroblastoma enter the same differential diagnosis. Additional immunohistochemical studies and correlation with morphologic and clinical data are required to reach a correct diagnosis. 
Background:
The oral cavity and oropharynx form one continuous chamber lined by an uninterrupted stratified squamous epithelium. Accordingly, the oral cavity and oropharynx have historically been viewed as a single compartment of the head and neck. The practice of combining these sites has recently been revised, largely owing to the observation that human papillomavirus (HPV)-driven carcinogenesis preferentially targets the oropharynx but not the oral cavity: HPV is detected in over 70% of oropharyngeal squamous cell carcinomas (SqCC) but in less than 5% of oral SqCCs. The purpose of this study was to determine whether HPV is evenly distributed across SqCCs of the oropharynx including those sites that do not harbor tonsillar tissues (e.g. soft palate). Design: A search of the medical records identified 30 primary SqCCs of the soft palate (n=29) and posterior pharyngeal wall (n=1). These were evaluated with p16 immunohistochemistry. P16 positive tumors were further evaluated with high risk HPV RNA in situ hybridization (RISH). Those tumors that were P16 positive (>70% staining) and HPV RISH positive were considered to be HPV positive. Results: 18 (60%) of the patients were male. The patients ranged in age from 46 to 81 years (mean, 60). 50% were Caucasian, 43% were African American, 3% were Asian, and 3% were Hispanic. 83% of patients were current or former smokers (average packyear history, 52). 80% of patients reported a history of alcohol use. By routine histology, 91% of the SqCCs showed surface dysplasia, and 88% were keratinizing or partially keratinizing. Only 1 tumor was p16 positive, but it was HPV negative by HPV RISH. In effect, none of the SqCCs were HPV related. Conclusions: HPV is not frequently detected in SqCCs of the soft palate. Based on comprehensive profiling (e.g. demographic, risk factors, histologic, HPV status), soft palate SqCCs more closely resemble those arising in the oral cavity than those arising in the lingual and palatine tonsils of the oropharynx. This observation: 1) supports the position that oncogenic HPV specifically targets the tonsillar crypt epithelium and not the squamous epithelium lining the surface of the oropharynx; 2) prompts consideration of further anatomic subtyping of the oropharynx based on the presence or absence of tonsillar tissue; 3) challenges indiscriminant HPV testing of all oropharyngeal SqCCs irrespective of anatomic subsite; and 4) suggests that rates of HPV in oropharyngeal SqCCs may vary depending on the anatomic distribution of the tumors within the oropharynx.
SOX10 and GATA3 Expression and Clinical Utility in Adenoid Cystic Carcinoma and Polymorphous Low Grade Adenocarcinoma of the Head and Neck
Ariana B Geromes, Rebecca Chernock, Katherine Kimmelshue, James Lewis, Kim Ely. Vanderbilt University Medical Center, Nashville, TN; Washington University School of Medicine, St. Louis, MO. Background: Discriminating between adenoid cystic carcinoma (AdCC) and polymorphous low grade adenocarcinoma (PLGA) can be difficult on small biopsy and cytologic specimens. SOX10 expression has been noted in myoepithelial cells of the salivary gland and prior studies have reported its utility in delineating two distinct subtypes of salivary gland tumors: acinic cell, adenoid cystic, epithelial myoepthelial carcinoma, myoepithelioma, and pleomorphic adenoma are positive, while salivary duct carcinoma and mucoepidermoid carcinoma are negative. There is scant data regarding SOX10 expression in PLGA. GATA3 reactivity can be seen in many types of salivary gland tumors, particularly mammary analogue secretory carcinoma and salivary duct carcinoma while AdCC does not express this marker. There is minimal data regarding GATA3 expression in PLGA, with a prior study reporting no staining in a small series of cases. We aimed to document GATA3 and SOX10 expression in PLGA and AdCC and determine whether these markers are of diagnostic utility in delineating these two entities.
Design: From electronic searches of department databases, we gathered 25 PLGA and 25 AdCC cases from resection specimens taken from 1994-2015. Diagnoses were confi rmed by at least 1 study pathologist. Immunohistochemical analyses for GATA3 and SOX10 were performed on whole tumor sections. Staining was scored on a 0-16 scale (intensity of staining [1] [2] [3] [4] multiplied by extent of staining [0-4]). A score of > 3 was considered positive. Results: SOX10 was expressed in 100% of PLGA and AdCC in a strong and diffuse manner with scores > 8 in 100% of PLGA and 88% of AdCC. GATA3 was expressed in 45% (10/25) of AdCC. When positive, GATA3 staining in AdCC was dim and patchy with scores < 8 in 80% of cases. A subset of PLGA cases, 20% (5/25), showed focal but strong GATA3 reactivity specifi cally in areas with ductal differentiation. The remaining PLGA cases were negative. Conclusions: Our study documents the expression of GATA3 and SOX10 in whole sections of PLGA and AdCC. SOX10 stains both AdCC and PLGA in a strong, diffuse fashion. GATA3 stains less than 50% of AdCC in a patchy, dim manner, while a subset of PLGA with ductal differentiation show focal, strong staining. Though interesting, this is not likely to be of clinical utility. In conclusion, SOX10 and GATA3 immunohistochemical stains do not appear useful in differentiating between AdCC and PLGA.
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PEComas of the Head and Neck: Diagnostic Challenges of a Rare Tumor with Variable Immunophenotype and Behavior Abigail L Goodman, Kelly R Magliocca, Christopher C Griffi th. Emory University, Atlanta, GA. Background: Perivascular epithelioid cell tumors (PEComas) are mesenchymal tumors occurring in a variety of sites but exceptionally rare in the head and neck (H&N). These tumors represent a signifi cant diagnostic challenge and criteria for predicting malignancy are not well studied. Here we review our experience with H&N PEComas focusing on immunophenotype and morphologic features. Design: A retrospective institutional archival study of PEComas of the H&N excluding cutaneous tumors was performed. Demographic information including patient age, sex, potential risk factors, anatomic location, prior imaging studies, treatment and clinical follow-up were abstracted. H&E and immunostained slides were reviewed for mitotic activity, necrosis, nuclear grade, and immunophenotype. Results: Three PEComas were identifi ed, all of which showed epithelioid morphology and had immunophenotypic evidence of melanocytic differentiation but negative S100 reactivity. One case was negative for muscle markers (smooth muscle actin and desmin). Two cases were classifi ed as malignant based on high nuclear grade, cellularity, and mitotic rate ≥ 1/50 HPF. The base of tongue tumor can be seen in fi gure 1 with Melan A and MITF reactivity. All patients were treated with complete tumor resection and malignant tumors received adjuvant radiotherapy. No recurrence or metastasis has been reported for either malignant tumor at 5 and 17 months. Background: Cutaneous Squamous Cell Carcinoma is the second most prevalent malignancy and most-frequently occurs in the head and neck (HNcSCC). Treatment of locally advanced or metastatic disease is associated with signifi cant functional morbidity and disfi gurement. There is limited understanding of the underlying genetic mechanisms in high risk HNcSCC.
Design: Targeted sequencing of 48 clinically relevant genes was performed on DNA extracted from formalin fi xed and paraffi n embedded non-metastatic high risk HNcSCCs. SIFT and PolyPhen output, existing genomic databases, functional and structural implications of detected mutations were considered in signifi cance determination. Observed genetic alterations were compared with data reported for physiologically normal skin and metastatic cSCC. Associations with clinicopathologic characteristics were evaluated. Results: We identifi ed somatic alterations in 44 cancer-associated genes. Missense variants comprised 72% of the mutations. Samples showed variability in number and type of genes affected. TP53 was mutated in all samples, APC, ATM, ERBB4, GNAQ, PTEN, PDGFRA, ABL1, FGFR3, KIT, NRAS, RB1 and VHL were altered in at least 50% of samples. Tumor suppressor alterations were most common in this cohort. The cell cycle/apoptosis pathway, mTOR, MAPK and PI3K pathways were most commonly altered. All samples with alterations in FGFR2 had peri-neural invasion. There were far fewer alterations in NOTCH genes and CDKN2A compared with metastatic cSCC. Somatic mutations associated with susceptibility to combined EGFR inhibitors, mTOR inhibitors, broad-spectrum tyrosine kinase inhibitors and DNA demethylating agents were identifi ed.
Conclusions:
The study provides an initial insight into the genomic landscape of nonmetastatic, high risk HNcSCC and identifi es targeted therapies that may merit further investigation in HNcSCC. It highlights the association of certain alterations such as FGFR2, NOTCH and CDKN2A that may play roles in local or distant cancer progression.
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Odontogenic There is a wide age range, with an average age of 25 to 30 years. The typical tumor is asymptomtic with painless jaw expansion, and found incidentally during dental examination. Diagnostic imaging may reveal a unilocular, multilocular or soap bubble lesion, displacing and/or resorbing teeth. The tumor is not encapsulated, infi ltrates bone and may require aggressive curettage. Design: Study population consisted of 6 males and 5 females (age range 11-62 years) with 6 mandibular and 5 maxillary tumors. The tumors ranged in size from 1.5 cm to massive involvement of the entire maxilla with extension to orbital fl oors. Tissue was available for routine, immunocytochemical (vimentin, MSA, SMA, S100 protein) and electron microscopic examination. Results: Gross examination demonstrated white to tan, gelatinous to mildly fi rm tumors with a mucinous character. The tumors were composed of stellate to ovoid to slightly spindled cells within abundant myxoid matrix with infrequent collagen fi bers. One tumor showed malignant transformation from typical odontogenic myxoma to an odontogenic myxosarcoma (low grade myxofi brosarcoma). Tumor cells expressed vimentin diffusely, focal SMA and focal MSA, and lacked S100 expression. Electron microscopy showed widely spaced cells with a mesenchymal character and scant cytoplasm. The tumor cells had adherent basal lamina material. The stroma was composed of ground substance with scant scattered collagen fi bers. The odontogenic myxosarcoma had markedly increased cellularity, more elongated spindle cells in close proximity, decreased ground substance and increased collagen fi bers. Conclusions: Odontogenic myxomas may be confused with other myxoid jaw neoplasms, such as myxoid nerve sheath tumor, chondromyxoid fi broma, myxoid fi brosarcoma and other myxosarcomas, especially when small biopsies are taken. Hyperplastic dental follicle with myxoid change, a dental papilla from a developing tooth or nasal polyp may be mistaken for an odontogenic myxoma. Review of diagnostic imaging of a jaw mass and clinical history are important in providing an accurate diagnosis and guiding appropriate surgical management.
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Salivary Duct Carcinoma and Invasive Ductal Carcinoma of the Breast: A Comparative Immunohistochemical Study Jalal B Jalaly, Souzan Sanati, Rebecca Chernock, Samir K El-Mofty. Washington University, Saint Louis, MO. Background: Salivary duct carcinoma (SDC) is a high-grade salivary gland malignancy with great morphological resemblance to invasive ductal carcinoma (IDC) of the breast. SDC is more common in men, but according to some reports they are more aggressive in women. When patients present with metastatic disease, the differential diagnosis may include both IDC and SDC. Rarely, female patients may have a past history of both SDC and IDC and may present with distant metastasis. Moreover, metastasis of SDC to the breast and IDC to the salivary (parotid) gland has been reported as well. Our aim is to develop an immunohistochemical panel that reliably distinguishes SDC from IDC. Design: All primary SDCs were included . Metastatic SDCs were included only if the primary tumor was a known SDC in the absence of available tissue from the primary site. Resection specimens from recent (2016), treatment naïve IDCs were included if they morphologically resemble SDC and were of grade 2 or 3 by Nottingham grade. All tumors were stained with androgen receptor (AR), estrogen receptor-alpha (ER-α), progesterone receptor (PR), HER-2, CK5/6, p63, and beta-catenin. Chi-square test was used for statistical analysis. Results: SDCs from 23 patients were included in the study (73.9% males) with an average age of 60.7 years (range 47 to 79 years). There were 29 IDCs (15 grade 2 and 14 grade 3, mean patient age of 53.6 years). A minority of cases of both SDC and IDC reacted to CK5/6 and p63. Both tumors were AR and beta-catenin (membranous) positive in more than 90% of cells. The main disparity in their immunohistochemical profiles was a distinctly different reactivity to ER-α, PR and HER-2. While 27 IDCs (93.1%) reacted positively to ER-α and/or PR, the majority expressing both (88.9%) with a 3+ intensity, only 2 SDCs expressed ER-α (8.7%) and 2 others expressed PR (8.7%) with an intensity of 1-2+ (P value <0.05) . On the other hand, 17 SDC (74%) were positive for HER-2 while only 5 (17%) IDC were positive (P value <0.05). Background: Head and neck paraganglioma accounts for <1% of all head and neck tumors. It usually has benign clinical course; however, malignant paraganglioma can only be diagnosed by showing metastatic disease. We undertook a retrospective study to assess the clinical significance of regional lymph nodes metastases in head and neck paragangliomas. Design: From 1993 to 2016, 63 primary head and neck paragangliomas were identified in our institution's pathology file. Patient clinical and histopathologic data were reviewed. Results: Of 63 patients, 49 were female and 14 were male (mean age of 54 yrs, range24 -78). Locations included: carotid body-30, glomus tympanicum-13, glomus jugulare-12, parapharyngeal space-3, infratemporal fossa-2, and 1 case each of larynx, skull base and pyriform sinus. 58 cases were classic and 5 were sclerosing variant. 32/63 cases (50%) had concurrent regional lymph node biopsies (1-29 lymph nodes). 4/32 (12%) showed metastatic paraganglioma (3 females, 1 male, mean age= 35), including 2 sclerosing variant cases. The primary locations were: 2 carotid body, 1 infratemporal fossa and 1 glomus tympanicum. There was no evidence of local recurrence or distant metastasis in the patients with positive lymph nodes with a follow up of up to 22 years (mean=12 years). 1/28 patient with negative lymph nodes developed lumbar spine metastasis 5 years later. 6/31 (19%) of patients without lymph node evaluation had local recurrence, most likely due to residual disease. Conclusions: The incidence of lymph node metastasis was 12%. Metastatic paraganglioma to regional lymph nodes may have an indolent clinical behavior, with disease free survival of up to 22 years. 40% of lymph node metastases were sclerosing variant indicating that this tumor may have a more aggressive clinical behavior. 1/59 (1.6%) , 28 patients with negative lymph nodes and 31 patients without lymph node sampling, developed distant metastasis. Clinical factors associated with metastasis were young age (mean 35 years, p=0.02), female gender, and carotid body location, although the age is the only parameter that was statistically significant.
HER2 Stain Scoring in Salivary Duct Carcinoma
The clinical utility of HER2 in SDC remains unclear. HER2 over-expression in SDC by immunohistochemistry (IHC) has been reported as a wide range. Thus far, a standardized HER2 IHC scoring system (SS) for SDC does not exist. HER2 SS for breast cancer (BC) and gastric/ gastroesophageal junction adenocarcinoma (GEC) have been developed separately by randomized controlled trials. Major scoring differences between these two exist [BC 3+: strong circumferential/complete membrane staining>10%; GEC 3+: strong complete, basolateral, or lateral membrane staining>10% in resection; regardless % in biopsy]. Pathologists have been adopting the BC SS for SDC due to its morphological resemblance to BC. There is no well-designed study regarding the rationale for this approach. Our aim was to assess the rate of SDC HER2 over-expression and evaluate scoring concordance using both BC and GEC SS. Design: A retrospective search was performed to identify SDC cases. HER2 IHC was scored by BC and GEC SS. Cases with score of ≥ 2, membrane staining completeness, and intratumoral heterogeneity (ITH, defined by 2 or more different HER2 scores with >10% of total tumor) were also evaluated. Results: 59 SDC cases (43 primaries, 3 recurrences, 13 metastases; 54 tissue resections, 5 biopsies) from 45 patients (M:F = 2:1; mean age = 64) were included. HER2 IHC over-expression by BC SS (determined on the primary resection if the score was different in other specimens) was: negative (0/1+) 15/45 (33%), equivocal (2+) 11/45 (24%), and positive (3+) 19/45 (42%). 2/59 demonstrated scoring discordance by BC and GEC SS due to strong but incomplete membrane staining: one resection with 2+ by BC SS and 3+ by GEC SS; one biopsy with 2+ by BC SS, 3+ by GEC SS (corresponding resection 3+ by both SS). Of 41/59 with a score of ≥2, 6 showed focally incomplete membrane staining; 26 demonstrated ITH. Additionally, 2 cases with 1+ score displayed incomplete strong membrane staining, but the low percentage (5%) was not significant enough to change the final score. Conclusions: In our series of 45 patients, HER2 overexpression by BC SS was seen in 42%. Strong incomplete membrane staining in SDC is uncommon, and mostly focal when present. Therefore, using HER2 BC SS appears to be appropriate for SDC. The presence of ITH in a substantial number of cases raises the concern that small biopsies may not be suitable for accurate scoring. Future HER2 testing by FISH on equivocal cases should establish the true gene amplification rate.
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Recurrent IDH2 Background: Sinonasal undifferentiated carcinoma (SNUC) is a rare aggressive malignant neoplasm that lacks well-established diagnostic criteria. SNUC is considered a diagnosis of exclusion once epithelial differentiation is identified and other entities have been excluded. The molecular pathogenetic basis for SNUC is unknown. Design: 11 cases of SNUC diagnosed between 2007-2016 with available tissue were identified in the archives. Diagnoses were confirmed by expert review of H&E slides and immunohistochemical (IHC) studies. DNA was extracted from FFPE samples for next-generation sequencing of all coding regions and selected introns for ~300 cancer genes. Institutional head and neck cohorts (n=412) were reviewed to explore mutational frequencies across relevant diagnoses. IHC using a multispecific antibody for IDH1/2 (R132/172) mutant protein was performed on 6 cases. Results: The patient group consisted of 6 men and 5 women, age range of 41-75 years (median 64). Tumor sites were nasal (5), nasopharynx (1) maxillary sinus (2), ethmoid sinus (2), sphenoid sinus (1). All SNUCs showed sheetlike or nested growth of medium-large cells with hyperchromatic vesicular nuclei, prominent nucleoli, and scant-to-moderate eosinophilic cytoplasm; necrosis and brisk mitotic activity were present. All tumors showed strong diffuse cytokeratin expression. Limited staining for p63/p40 (1/10), synaptophysin (2/10), chromogranin (3/9), and S-100 (2/9) was seen. Negative IHC included desmin (0/7), NUT (0/8), and EBER (0/6); INI1 (SMARCB1) was retained (7/7). Sequencing identified IDH2 R172 mutations in 6 (55%) SNUCs: R172S (3), R172T (2), and R172M (1). By IDH1/2 IHC, 3/3 SNUCs with R172 mutations were positive; 3 wild-type cases were negative. Genetic alterations in IDH2 wild-type cases included 1 tumor with a SMARCA4 splice variant (with confirmed loss of SMARCA4 expression by IHC) and 1 case with a NOTCH1 PEST domain mutation. Review of sequencing data for the head and neck cohorts confirmed absent IDH activating mutations in other tumor types. Conclusions: SNUCs are a genomically heterogeneous class of tumors; however, our findings suggest that a limited number of pathway alterations lead to a similar cancer phenotype. IDH2 R172X mutations are a dominant finding in SNUCs and are specific to SNUCs in the differential diagnosis with other malignant neoplasms of the head and neck. The identification of frequent IDH2 mutations in SNUC has significant diagnostic and therapeutic implications. 
Design:
The surgical pathology archives were searched for low grade salivary gland adenocarcinoma including MASC showing predominantly papillary cystic pattern during a period from 2005 to 2016.. The electronic medical records were reviewed for demographic information. The H&E, IHC and FISH were studied for the presence of ETV6-NTRK3 break apart fusion product. Results: Of 31 cases of LG adenocarcinoma with papillary cystic pattern, upfront diagnosis of MASC was offered in 18 cases. These were confirmed by IHC and molecular study. Diagnosis of AciCC with papillary cystic pattern was reported in 12 cases and papillary cystadenocarcinoma in one case. These cases were reclassified as MASC after IHC and molecular testing. All the sections showed diffuse strong positivity for mammaglobin, CK7 and S100 with negativity for DOG1 and P63. Luminal positivity for MUC 4 was noted in 93.5% cases; uninterpretable in 6.5% cases due to tissue depletion. 77.4%cases showed ETV6 split signals. FISH was uninterpretable in 22.6 % cases due to more than six years old archival blocks and depletion of the tumor tissue. Parotid was primary site in 77.4% followed by submandibular glands (12.9%) and hard palate(9.6%). Conclusions: MASC is a distinctive SGT with defining molecular translocation. Our study highlights that papillary cystic variant of AciCCs can masquerade as MASC if classified solely on the architectural growth patterns. IHC and molecular studies are mandatory to rule out MASC. More studies from different geographic areas are necessary to understand tumor biology.
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The Landscape of Genomic and Transcriptomic Alterations in Esthesioneuroblastomas Jisun Kim, Kathleen A Burke, Rodrigo Gularte-Merida, Felipe Geyer, Fresia Pareja, Britta Weigelt, Fernando Schmitt, Brian P Rubin, Ilan Weinreb, Jorge Reis-Filho. Memorial Sloan Kettering Cancer Center, New York, NY; Laboratoire National de Santé / Luxembourg -Anatomie Pathologique, Luxembourg, Luxembourg; Cleveland Clinic, Cleveland, OH; University Health Network, Toronto, Canada. Background: Esthesioneuroblastoma (ENB) is a rare malignancy originating from olfactory neurosensory cells. The repertoire of genetic alterations in ENBs remains to be elucidated. The aim of this study is to investigate whether ENBs are driven by highly recurrent somatic mutations or fusion genes. Design: Representative frozen sections of six ENBs and adjacent normal tissue were microdissected. DNA samples were extracted from tumor and normal tissues and successfully subjected to whole-exome sequencing in five cases. RNA samples were extracted from six ENBs and subjected to RNA-sequencing. Somatic singe nucleotide variants were identified with MuTect, small insertions/deletions using Strelka and VarScan 2, and copy number alterations using FACETS. Cancer cell fractions were inferred using ABSOLUTE. Expressed fusion genes were detected using deFUSE and INTEGRATE. Selected mutations and fusion genes were validated by means of Sanger sequencing and reverse transcription PCR, respectively. Results: 191 non-synonymous somatic mutations were identified across 184 genes among which 73 mutations were validated by RNA-sequencing. Seventeen recurrent and/ or pathogenic somatic mutations were validated by Sanger sequencing (MACF1,
ANKHD1, ARHGEF9, ATM, CNOT10, CSDM1, DCTN1, ITSN1, LMTK2, MAP2K1, MMRN2, MYOCD, RCE1, RORB, SDCCAG8, ZNF471).
The microtubule actin crosslinking factor 1 (MACF1) gene was found to be recurrently mutated; both mutations were missense and coupled with loss of heterozygosity of the wild-type allele. RNAsequencing revealed 223 fusion transcripts, of which an inter-chromosomal in-frame DHRS2-GSTM2 fusion gene was found to be recurrent in two low-grade ENBs. Conclusions: ENB is a genetically heterogeneous disease. One recurrent somatic inactivating MACF1 mutation was identified in two ENBS, and a validated expressed DHRS2-GSTM2 fusion gene was identified in two low-grade ENBs. Further studies assessing the prevalence of these recurrent alterations in a large cohort of ENBs are warranted. Background: Fine needle aspiration (FNA) is a well-established method for the rapid diagnosis of an ultrasound visualized thyroid lesions. A rare occurrence, however, is the near-complete infarction after FNA with subsequent obscuration of histopathological diagnosis. In this study we present one of the largest series of such post-FNA infarctions and our experience with subsequent diagnosis using next generation sequencing for BRAF V600E mutations. Design: Nine thyroid lesions with extensive to near complete infarctions were identified from our institutional database from 2010 to 2015. From formalin fixed paraffin embedded tissue, tissue was extracted and examined using next generation sequencing for BRAF V600E mutations.
BRAF V600E Mutations in Infarcted Thyroid Carcinoma
Results:
The clinicopathological results are shown in Table 1 . The cohort consisted of 2 males and 7 females with a mean (median) age of 53 (55 years). The mean (median) size of lesions was 29 (25 mm). The mean (median) time between FNA and surgery was 35 (38 days). All lesions were infarcted showing complete (~100%), near total (>90%) and extensive (>60%). Overall we found BRAF V600E mutations in infarcted tissue in 44% of cases (4/9). Background: Tumor immune response and tumor metabolism both affect survival in head and neck squamous cell carcinoma (HNSCC). We assessed interdependencies and prognostic significance of specific immune and metabolic gene signatures within The Cancer Genome Atlas (TCGA) and evaluated underlying signaling mechanisms linking tumor metabolism with immune response in a tumor spheroid/immune cell co-culture model. Design: Anti-tumor immune response (CD8A) and anaerobic/glycolytic (GLUT1) as well as aerobic (COX5B) tumor metabolism markers were defined according to mRNA up-and down-regulations within the TCGA HNSCC databank. Short-term (20 months) and long-term (60 months) survival were calculated by the Kaplan-Meier method. ROS production of HNSCC cells after glycolysis inhibition by 2-Deoxyglucose (DGL) and ex vivo radiation treatment was measured and chemotaxis of human peripheral blood mononuclear cells (PBMC) to HNSCC spheroids was evaluated in the presence or absence of the ROS scavenger N-acetylcysteine (NAC).
The TCGA HNSCC databank analysis included 522 patients. CD8A was more frequently decreased in tumors with high GLUT1 (p<0.0001). COX5B had no effect on CD8A. While neither COX5B, nor GLUT1 alone had an impact on outcome, patients with increased CD8A presented with improved long-term survival (p=0.049). A patient subgroup with a favorable immuno-metabolic gene signature (high CD8A, high COX5B, low GLUT1) showed improved short-term (p=0.013) and long-term (p=0.048) survival in comparison to patients with an unfavorable gene signature (low CD8A, low COX5B, high GLUT1). Furthermore, the expression level of the H 2 O 2 producing enzyme superoxide dismutase 2 (SOD2) was more frequently up-regulated in tumors with a favorable gene signature (p=0.047) implying an involvement of ROS. In vitro, ROS production increased, alone and synergistically, with DGL treatment and radiation. In spheroid/immune cell cocultures, DGL treatment combined with radiation led to increased PBMC chemotaxis to HNSCC spheroids. Addition of NAC abrogated this effect indicating a ROS-related signaling mechanism. Conclusions: Survival following chemoradiotherapy is determined in part by an interplay between tumor metabolism and immune response, potentially via ROSmediated signaling.
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Expression of Cancer Stem Cell Markers in Salivary Gland Basal Cell Adenocarcinoma and Basal Cell Adenoma
Sook-kyung Kwon, Allyn M Lambertz, Robert Robinson. University of Iowa Hospitals and Clinics, Iowa City, IA; The University of Iowa Carver College of Medicine, Iowa City, IA. Background: Emerging studies have characterized a population of tumorigenic cancer stem cells (CSC) that have the ability to initiate and drive tumor progression in salivary gland malignancies. A sub-population of CSCs have been described in some salivary gland neoplasms but CSC expression in basal cell adenocarcinomas (BCAC) and basal cell adenomas (BCA) has not been sufficiently investigated. These two neoplasms appear cytologically similar but are separated primarily by the presence of invasion in BCAC. In this study, we examined immunohistochemical expression of CSCs in BCAC and for comparison, in the cytologically similar tumor, BCA. Design: Tissue microarrays of 30 BCAs and 19 BCACs were constructed from paraffin blocks and examined by immunohistochemistry for ALDH, BMI1, CD44, CD133, OCT4, and Podoplanin. Staining on triple replicates of tissue cores were performed and scored, blinded by the diagnosis, based on the intensity of staining (0-3) and percentage (0-100%), to obtain an H-score (intensity x percentage) of 0-300. The mean H-scores were calculated for BCAs and BCACs and compared using the Student's t-test. The Mann-Whitney U-test was used to compare the median H-scores for BCAs and BCACs. Statistical tests were 2-tailed with p-values <0.05 considered significant. Results: CSC expression in BCAs and BCACs is summarized in Table 1 . The median H-scores for ALDH, CD44, and Podoplanin expression in BCA and BCAC were significantly different (p values 0.009, <0.001, and 0.007, respectively), though mean H-scores for these CSC markers were <100 in both tumors. No significant difference in median H-scores for BMI1 and OCT4 was seen in BCA compared to BCAC. 
Conclusions:
The expression of ALDH, CD44, and Podoplanin is significantly greater in BCAC compared to BCA, however the mean H-scores for these three markers were <100 in both tumors. From this study it appears that both BCAC and BCA have relatively low levels of expression of CSC markers yet BCAC shows significantly higher expression, suggesting a true difference between these neoplasms at the molecular level which may relate to differing histologic and biologic behavior.
Computer Extracted Features of Nuclear Architecture in H&E Sectionsare Predictive of Disease Specific Survival Inoral Cavity Squamous Cell Carcinoma Patients
Cheng Lu, James Lewis, Anant Madabhushi. Case Western Reserve University, Cleveland, OH; Vanderbilt University Medical Center, Nashville, TN. Background: Oral cavity squamous cell carcinoma (OCSCC) is one of the most common head and neck carcinomas, and its morbidity and mortality are increasing worldwide. Prognosis remains poor despite advances in treatment. Histologic features associate with prognosis, but only modestly, when assessed visually by pathologists. In this study, we present preliminary findings that patients with aggressive tumors can be distinguished from those with more indolent ones using nuclear architecture features assessed by computerized analysis of digitized H&E stained sections. Design: A tissue microarray of 115 primary OCSCC was digitally scanned and 50 cases selected at random for modeling with the other 65 for validation. Nuclei were segmented using a watershed method and local/global graphs were constructed based on the centroids of segmented nuclei. Based on the nuclei graph, nuclear architectural features were extracted and analyzed, and the features most discriminative of patient death from disease were utilized to train a classifier. The five best quantitative histomorphometric features were identified using Wilcoxon rank sum test within the training cohort. A quadratic discriminant classifier (Oral Cavity Histomorphometric-Based Image Classifier or OHbIC), was created and validated in the independent cohort of 65 patients.
Results:
The five best quantitative histomorphometric features are all from a feature set which captures statistics of co-occurrence nuclei with similar morphology. In univariate survival analysis, OHbIC positive patients had significantly poorer disease-specific survival (p=0.0268). In multivariate analysis, controlling for the major prognostic variables such as T and N-classification and resection margin status, positive OHbIC results were independently predictive of poorer disease-specific survival [hazard ratio with 95% CI = 11.023 (2.62-46.38); p=0.001] . Conclusions: Computerized histomorphometrically-derived features of nuclear architecture derived from digitally-scanned tumor H&E slides are strongly and independently predictive of patient survival in OCSCC. This may form the basis for a future predictive image analysis classifier that can be used in tailoring treatments for OCSCC patients.
HPV Genotyping in Head and Neck Papillomas(HNP): An Institutional Experience
Abul Ala Syed Rifat Mannan, Dana Gao, Aneta Waluszko, Wenjing Shi, David Y Zhang, Fei Ye. Mt Sinai Hospital, New York, NY. Background: HPV infection is a major risk factor for development of benign and malignant mucosal head and neck lesions. There is limited data on association of HPV with benign HNPs. Here we report frequency of HPV subtypes in HNPs diagnosed at our institution. Design: Clinical and pathologic features were reviewed for HNPs diagnosed between 2012 and 2015.Maxwell 16 FFPE Tissue LEV DNA Kit was used for DNA tissue extraction, and Real-time PCR testing with pan-HPV primers (GP5+ and GP6+) and primers/probes specific for HPV16 and HPV18, followed by Sanger sequencing of samples positive for HPV but negative for HPV16/18, was used for HPV genotyping. Results: 100 cases of HNPs were genotyped(73 males,23 females,average age 47.4 yrs, range 6-78 yrs). Of these 93 were benign HNPs and 7 were inverted papillomas. Locations included oral cavity (n= 23), tongue (n= 8), tonsil (n= 9), oropharynx (n=6), larynx (n= 35), sinonasal tract (n= 19, including 7 inverted papillomas).HPV DNA was positive in 37 cases (37%).HPV 6 was most prevalent (n=19;51.4%), followed by HPV11(n=10; 27%),HPV16 (n=5; 13.5%),and HPV32 (n=1; 2.7%).HPV subtype was indeterminate in 2 cases (5.4%).Tongue (62.5%) and larynx (57.1%) showed highest HPV positivity. Of the 5 HPV 16 + cases, 2 had associated squamous cell carcinoma (SCC) of the tonsil, 1 had SCC of skin (neck); 2 had no known associated cancers. Of HPV positive cases, 75.7% (28/37)were male and 24.3% (9/37)female. p16 IHC was done in 10 cases (negative 1, weak 6 and diffuse strong 3). Diffuse positivity was seen in those with HPV 16. Background: Hyams grading is considered a prognosticator in olfactory neuroblastoma (ONB), but grading criteria are subjective, and predate ancillary testing and modern surgical approaches. We propose detailed grading criteria definitions and apply them to a unique cohort treated mainly by endonasal endoscopic approach (EEA). Design: 50 of 69 ONB seen in a 22 year period at our institution had primary tumor available for review. The majority (75%) were treated surgically by EEA and received adjuvant radiotherapy (90%). Mean follow-up was 59.2 months. A traditional Hyams grade had been assigned in 68% (34/50) cases. A modified version of the Hyams grading was developed (Table 1 ) and utilized to assign each tumor a score of I-IV. Clinicopathologic parameters were correlated with outcomes using univariate Cox regression analysis. Background: NKX2.2 is a new marker for Ewing sarcoma/PNET that has been reported to be sensitive and specific. It has not, however, been investigated specifically in the sinonasal small round blue cell tumor (SRBCT) differential diagnosis which includes many tumors specific to that site, including olfactory neuroblastoma, SNUC, and teratocarcinosarcoma. It has also not been investigated in the newly-described adamantinoma-like variant of Ewing sarcoma. Design: Immunohistochemistry for NKX2.2 was performed on 169 poorly differentiated sinonasal neoplasms: 73 squamous cell carcinomas (67 poorly differentiated, nonkeratinizing, or basaloid types and 6 nasopharyngeal carcinomas), 46 olfactory neuroblastomas, 8 sinonasal undifferentiated carcinomas (SNUCs), 6 melanomas, 7 Ewing sarcomas, 6 SMARCB1-deficient carcinomas, 5 teratocarcinosarcomas, 5 alveolar rhabdomyosarcomas, 4 solid adenoid cystic carcinomas, 4 NK/T cell lymphomas, 3 NUT midline carcinomas, and 2 small cell carcinomas. Results: NKX2.2 was positive in 7 of 7 (100%) Ewing sarcomas, including 4 adamantinoma-like variant (all diffuse, 4 strong and 2 weak). It was also positive in 4 of 5 (80%) teratocarcinosarcomas (always strong but focal), 12 of 46 (26%) olfactory neuroblastomas (all diffuse, 2 strong and 10 weak), 4 of 6 melanomas (2 diffuse, 2 focal, all weak), and 1 of 2 small cell carcinomas (diffuse and strong). All squamous cell carcinomas, NUT midline carcinomas, SMARCB1-deficient carcinomas, SNUCs, solid adenoid cystic carcinomas, NK/T cell lymphomas, and alveolar rhabdomyosarcomas were negative. Conclusions: In the sinonasal SRBCT differential diagnosis, NKX2.2 is a useful and very sensitive marker for Ewing sarcoma/PNET including the adamantinoma-like variant. At the same time, it is not entirely specific, as it will be positive in a subset of other neuroendocrine/neuroectodermal tumors. As a result, NKX2.2 must be utilized as part of an immunohistochemical panel with other markers, especially cytokeratins, melanoma markers (such as S100, Melan-A and SOX10), and CD99.
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Novel Mutations in Sinonasal Squamous Cell Carcinoma Detected Using Next Generation Sequencing Gordon AG McKenzie, Taneisha McFarlane, Sandra Hing, Geraldine Thomas, Ann Sandison. Imperial College London, London, United Kingdom; Hull and East Yorkshire Hospitals NHS Trust, Hull, East Yorkshire, United Kingdom. Background: Sinonasal squamous cell carcinomas (SNSCCs) comprise 80% of sinonasal malignancies. The histopathological distinction between entities, including inverted sinonasal papilloma (ISP) and low-grade SNSCC lacks clarity, adding complexity to surgical management decisions. In this pilot study, we employed nextgeneration sequencing (NGS) in effort to identify novel molecular aberrations within the ISP-SNSCC spectrum, which could serve as biomarkers or potential therapeutic targets. Design: DNA was extracted from archived formalin-fixed paraffin-embedded specimens from 10 patients creating a cohort of ISPs with and without atypia, sinonasal mucosal dysplasia, low-grade SNSCC, well-and poorly-differentiated SNSCC. Targeted NGS was performed using the Life Technologies' Ion AmpliSeq™ Cancer Hotspot Panel v2 as a sequencing library. Raw sequencing data was captured using Ion variant caller and comparatively analyzed, with reference to the Catalogue of Somatic Mutations in Cancer (COSMIC) database. Results: There were 121 variants detected (range 2-73 per sample) where 18 (15%) were intronic and excluded. Twenty (17%) COSMIC mutations from 14 genes were identified and none had specifically been reported in SNSCC. Six genes with COSMIC mutations were known to be associated with SNSCC (TP53, RB1, AKT1, PIK3CA, MET and CDKN2A). To the best of our knowledge, we detected eight previously unassociated genes with COSMIC mutations (ATM, IDH1, PTPN11, RET, VHL, FBXWL, APC and FLT3) . A COSMIC missense mutation in ATM (c.1009C>T) was present in both an ISP and unpaired low-grade SNSCC. An apparent missense single nucleotide variant was identified in SMARCB1 (c.215C>A), which was detected in an ISP, two ISPs with atypia and residual atypia following resection of a low-grade SNSCC. An insertion in EGFR (c.2308_2309insACAACCCCC) was found in an ISP (and its associated dysplasia), a low-grade SNSCC and a frank SNSCC. Conclusions: NGS can be employed to detect novel mutations in the ISP-SNSCC spectrum, which has hitherto been understudied. We demonstrate previously unreported COSMIC mutations in eight genes. The potential of the SMARCB1 variant detected to serve as a biomarker of atypia is interesting, as SMARCB1 loss of function has been noted in sinonasal carcinomas with rhabdoid cytomorphology. The finding of a specific cancer-associated insertion in EGFR across the ISP-SNSCC spectrum further supports its potential as a biomarker of impending malignancy.
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HMGA2 Is a Specific Immunohistochemical Marker for Pleomorphic Adenoma and Carcinoma Ex-Pleomorphic Adenoma
Jeffrey Mito, Vickie Y Jo, Paola Dal Cin, Jeffrey F Krane. Brigham and Women's Hospital, Boston, MA. Background: The accurate classification of salivary gland neoplasms is often challenging due to the morphologic heterogeneity of these tumors. Previous studies have identified recurrent translocations involving High Mobility Group A2 (HMGA2) in a subset of pleomorphic adenomas (PA) and carcinoma ex-pleomorphic adenomas (CA ex-PA). We evaluated the frequency of HMGA2 expression in PA and CA ex-PA and determined the potential diagnostic utility of HMGA2 immunohistochemistry in a broad panel of salivary gland tumors. Design: 190 salivary gland tumors including: PA (50), CA ex-PA (25), adenoid cystic carcinoma (27), basal cell adenoma (BCA) (19), salivary duct carcinoma (13), polymorphous low grade adenocarcinoma (12), mucoepidermoid carcinoma (12), acinic cell carcinoma (11), epithelial-myoepithelial carcinoma (9), mammary analogue secretory carcinoma (6), myoepithelioma (3), basal cell adenocarcinoma (1), sarcoma ex-PA (1), and oncocytoma (1) were identified and immunohistochemical staining for HMGA2 was performed. The presence and extent of nuclear staining was evaluated. FISH for HMGA2 rearrangement was performed on a subset of tumors. Results: Nuclear HMGA2 expression was identified in 14 PAs (28.0%) and 6 CA exPAs (24.0%). HMGA2 expression was strong and diffuse throughout all PAs and half of the cases of CA ex-PA. In the remaining 3 cases of CA ex-PA, HMGA2 showed limited weak-to-moderate multifocal staining within the carcinomatous component, while strong and diffuse HMGA2 expression was retained in residual PA. One case each of myoepithelioma and BCA showed strong and diffuse expression of HMGA2. Review of both cases suggested they may represent misclassified PAs as ductal structures were identified in the case of myoepithelioma and the BCA lacked evidence of an activating β-catenin mutation. Both cases were reclassified as PA. Among the remaining salivary gland tumors: 3 de novo salivary duct carcinomas (23.1%) and 3 epithelial-myoepithelial carcinomas (33.3%) showed limited HMGA2 expression. FISH for HMGA2 rearrangement was successfully performed on a subset of tumors and showed that diffuse HMGA2 expression in PA and CA ex-PA was associated with rearrangement of the HMGA2 locus in 2 of 2 tested PA/CA-ex PA cases, while 2 cases of de novo salivary duct carcinoma with limited HMGA2 expression and 1 case of CA ex-PA without HMGA2 expression showed no rearrangement of the HMGA2 locus. Conclusions: Strong and diffuse HMGA2 protein expression is a specific (99.1%) marker for PA and CA ex-PA that correlates with rearrangement of the HMGA2 locus.
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LEF1 Is S Sensitive Marker of Cribriform Morular Variant of Papillary Thyroid Carcinoma
Shalini Mohindra, Hany Sakr, Charles D Sturgis, Christine N Booth, Deborah Chute. Cleveland Clinic, Cleveland, OH. Background: Cribriform morular variant of PTC (CMVPTC) activates the CTNNB1/ Wnt pathway with nuclear accumulation of B-catenin and LEF1. The utility of LEF1 in the diagnosis of CMVPTC has not been previously studied. Design: IHC for LEF1 was performed on 7 CMVPTC, 15 normal, 6 CLT, 5 Graves,25 NH, 30 PTCs, 25 FC, 25 HCC and 21 UTC. LEF1 immunostain was scored based on the intensity of the stain (0= no nuclear stain, 1= weak nuclear stain, less than a lymphocyte and 2= strong nuclear stain, as intense as a lymphocyte) and percentage of cells positive at each intensity, for a maximum total score of 200. Results: Please see tables 1 for results of LEF1 IHC staining. The sensitivity(SS) and specificity(SP) of LEF1 to differentiate PTC and CMVPTC is presented in table 2. The best clinical threshold is ≥30% at 2+ with a SS and SP of 85.7% and 98%, respectively. One CMVPTC was negative for LEF1 and nuclear beta-catenin. If excluded, the SS and SP both increased to 100%. LEF1 staining by total score and mean % intensity A CMVPTC 20x; B CMVPTC LEF1 20x; C Classical PTC 20x; D Classical PTC LEF1 Conclusions: LEF1 immunostain is highly sensitive and specific for CMVPTC, especially in the setting of a PTC neoplasm. The pattern of staining is important with ≥ 30% of cells showing strong nuclear staining.
Traditional Grading of Oropharyngeal and Non-Oropharyngeal Squamous Cell Carcinomas in the HPV Era
Kathleen Montgomery, Mitra Mehrad, Krystle Lang Kuhs, James Lewis. Vanderbilt University Medical Center, Nashville, TN. Background: In recent years, HPV-positive oropharyngeal squamous cell carcinoma (HPV+OPSCC) has become recognized as a distinct clinical entity, differing from HPV-negative OPSCC in molecular pathophysiology, epidemiology, and prognosis. The histologic grade, or differentiation, of head and neck SCC (HNSCC), including OPSCC, has been found to correlate with survival, albeit modestly, and CAP and RCPath recommend reporting a grade for all HNSCC. Few studies, though, have investigated traditional grading of OPSCC in the HPV era. Since most HPV+OPSCC appear poorly differentiated by classical grading while having a better prognosis than HPV-SCC, traditional grading may not be of value. Design: Digitally-scanned tissue microarrays (2 mm and 0.6 mm punches) of H&E stained slides from 291 retrospectively identified HNSCC patients were examined: 151 HPV+OPSCC (p16 and mRNA in situ hybridization [ISH] dual positive), 42 HPV-OPSCC (p16/mRNA ISH dual negative) and 60 non-OPSCC. One study head and neck pathologist provided each a histologic grade (well-, moderately-, or poorlydifferentiated) and also assessed keratinization, tumor-stroma ratios, and nest size (1, 2, or 3). The association between histologic features and overall (OS) and disease-specific survival (DSS) were evaluated in Cox proportional hazard models. Results: Of the 291 cancers graded, 15 were well-(WD), 138 moderately-(MD), and 138 poorly-differentiated (PD). In univariate analysis, PD cases had increased overall (p=0.01) and disease-specific (p=0.02) survival, but these associations were not present after controlling for HPV status. No association between tumor grade and survival was found in subgroup analyses performed after stratification by HPV status and tumor site. Similar findings were observed with degree of keratinization, and neither tumor:stroma ratio nor nest size correlated with survival. Conclusions: In our cohort, PD and keratin-absent tumors had increased overall and disease-specific survival over WD/MD ones. However, HPV+OPSCC tends to be poorly differentiated and lack keratin, yet have a favorable prognosis. The fact that grade was not prognostic after controlling for HPV status or in subgroup analysis suggest that, although it is widely recommended to provide grade in routine pathology reporting, it may not be useful in either HPV+OPSCC or in HNSCC more broadly.
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Sinonasal Small Cell Neuroendocrine Carcinoma (SNEC): Clinicopathological Study of 37 Cases Ashvini Natu, Asawari Patil, Munita Bal, Rajiv Kumar, Shubhada Kane. Tata Memorial Centre, Mumbai, Maharashtra, India. Background: SNEC is a rare but aggressive tumor of sinonasal tract. Though it shows histomorphology similar to its pulmonary counterpart, it is a close differential diagnosis for olfactory neuroblastoma (ONB) along with other poorly differentiated carcinoma like sinonasal undifferentiated carcinoma (SNUC) and poorly differentiated squamous cell carcinoma. In this study we describe the clinicopathological profile of 37 cases of SNEC diagnosed at a tertiary cancer center. Design: All cases of SNEC diagnosed in our institute from January 2011 to August 2015 were retrieved from pathology archives. The hematoxylin-eosin(H-E) slides as well as immunohistochemistry(IHC) slides were reviewed. Histopathological parameters reviewed include: architectural pattern, cytomorphological features (including cell type, cytoplasm, nuclei and nucleoli), presence of necrosis, atypical mitosis and apoptosis. Clinical details and radiological findings were obtained from electronic medical records. Results: Thirty seven cases of SNEC were identified, with a male to female ratio of 3.6:1 and an age range of 19-68 years(mean=44.3 years). The duration of symptoms was known in 32 cases, ranging from 15 days to 2 years(mean=4.8 months). The commonest site was nasal cavity(16 cases) followed by maxilla(10 cases), ethmoid(5 cases), frontal(1 case) and sphenoid(1 case). Four cases showed tumor involving multiple sites. Radiological findings were known for 34 cases, of which 16 cases showed intracranial extension while 17 cases showed intraorbital extension. The commonest architectural pattern was tumor cells in sheets, nests and clusters. Cells were usually small to medium sized, round to oval shaped with scanty cytoplasm. Majority of the cases showed hyperchromatic nuclei with indistinct nucleoli. Increase in mitoses with atypical mitoses and apoptosis was seen in most of the cases. Necrosis was common (seen in 28 cases). Nine cases showed desmoplastic reaction in stroma. Two cases showed an unusual morphological feature -pagetoid spread of tumor cells in the overlying mucosa, which was confirmed by IHC. This feature has not been described in literature. Features seen in ONB such as rosette formation and neurofibrillary matrix, were not seen in any of these cases. IHC studies were available in all 37 cases. The commonest markers expressed were Pancytokeratins (AE1/AE3, CK) and one or more neuroendocrine markers (Synaptophysin, Chromogranin, CD56, NSE) . Conclusions: SNEC needs to be differentiated from other small round blue cell malignant tumors of sinonasal tract as it is associated with poor outcome and needs multimodal treatment.
1325
Warthin's Tumor of the Parotid Gland: A Simple Lesion with Complex Clinical Implications; a Clinical Pathologic Review Anam Naumaan, Ritu Ghai, Paolo Gattuso. Rush University Medical Center, Chicago, IL. Background: Warthin's tumor (WT) is the second most common benign tumor of the salivary glands, majority involving the parotid gland. Characteristic clinical features include, painless, slow growing lesion which can be multifocal and bilateral. However, the clinical significance of a diagnosis of WT is not well understood or studied. We investigated the relationship between WT and synchronous or metachronous salivary and extra-salivary gland lesions associated with this neoplasm and their clinical significance.
Design: Between 1993 to September 2016, the pathology files at our institution were reviewed for a diagnosis of WT. The clinical and pathologic data was reviewed in detail for other lesions occurring in patients with diagnosis of WT, either at the same time/ within the same year (synchronous), or at another time (metachronous). Results: A total of 63 cases of WT were identified (42 males, 21 females), with the age ranging from 32 to 78 years. 22 cases (35%) with additional lesions were identified. Of these 22, 15(68.2%) were synchronous, 5(22.7%) metachronous, and 2(9.1%) were both synchronous and metachronous lesions. In cases with metachronous lesions, the second lesion was diagnosed within 5 years of diagnosis of the first lesion, with only 1 case where the second lesion was diagnosed at 9 years. There were 3(13.6%) cases with 3 lesions each. Of 22 cases, 11(50%) had head and neck tumors, 6(27.3%) had lung tumors, 3(13.6%) had hematologic malignancies, while there was one case each of myxoinflammatory sarcoma, breast cancer with renal cancer, and sarcoidosis. Of the 11 head and neck tumors, 7(63.6%) were malignant (5 squamous cell carcinoma, 2 ductal type adenocarcinoma) and 4(36.4%) benign (2 pleomorphic adenoma, 2 lymphoepithelial cysts); (8 synchronous, 3 metachronous). Of the 6 lung tumors (5 synchronous, 1 metachronous) there were 4(66.7%) cases of adenocarcinoma and 2(33.3%) of small cell carcinoma. The hematologic malignancies included 2 metachronous (1 case of CLL and Hodgkin's lymphoma, respectively) and 1 synchronous B-call lymphoma. It was also noted that in 6 out of 7 metachronous lesions, WT was not the first lesion. Conclusions: Analysis of our data shows that there is an association of WT with other tumors, either synchronous or metachronous. The most common association is with head and neck tumors, and lung carcinomas. It might be helpful to screen or follow up patients with WT for other head and neck tumors, as well as lung carcinoma following a diagnosis of WT.
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NIFTP Background: In March 2016, after conducting an international retrospective study on encapsulated follicular variant of papillary thyroid carcinoma (EFVPTC), a panel of experts made the case for reclassifying some EFVPTC as non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), changing the nomenclature from a malignant to a non-malignant entity Following publication of the JAMA paper, many requests to review cases for re classification were received from clinicians which prompted this review of cases. We also assessed the workload involved in the slide review. Design: A 10 year (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) search of all papillary thyroid carcinoma (PTC) thyroid resection histology reports was performed. Cases were selected as potential NIFTP candidates based on report review alone. Following this initial triage, the slides of the remaining cases were reviewed independently by two consultant histopathologists and the number of slides required to complete the review was recorded. Once a single exclusion criterion was met, no further slides were reviewed. Results: Of the 545 reports reviewed, 71 cases were identified as potential NIFTP cases.49 cases were external cases and histology was not available. Of the remaining 22 cases, 5 (22.7%) met the criteria for reclassification as NIFTP. 17 cases were excluded based on the histologic criteria as listed in table 1.
Exclusion Criteria
Number of cases excluded
Capsular invasion 6
Papillary growth>1% 5
Solid trabecular growth pattern >30% 4
Psammoma bodies 1
Capsule not adequately sampled 1
The 17 non NIFTP cases required review of 114 slides, range 2-28, mean 6.7, median 5.5 slides per case; 5 NIFTP cases where all slides were reviewed required review of 58 slides range 7-20, mean 11.6, median 12 slides per case Conclusions: NIFTP accounted for 0.9% of all PTCS over this 10 year period. Review of just the reports was sufficient to exclude NIFTP in the majority of cases, and in those that required slide review, exclusion criteria were identified after review of an average of 5.7 slides per case. The issue of availability of external material is a limitation in a tertiary referral centre. Warthins tumor, 4 AdCC, 5 Salivary duct adenocarcinoma (AdCA), 2 BCA, 6 normal salivary gland controls]. Specifi c primers for PLAG1 and HMG2 were designed and tested in tumor cell lines. mRNA levels of the genes were measured by quantitative reverse transcription polymerase chain reaction, and compared between salivary gland neoplasms and control groups. Results: PLGA1 and HMGA2 levels in the control group were 0.80 ± 0.34 (mean ± SD) and 0.04 ± 0.07, respectively. An empirical cutoff of four times of the control PLGA1/ HMGA2 means (4 x mean) was implemented to categorize cases with known histological diagnoses as positive (at least one measure was greater than 4 x mean) or negative (both PLGA1 and HMGA2 levels were lower than 4 x mean) for over-expression. The 4 x mean cutoff identifi ed 56.5% of PA, 66.7% of EXPA, 40% of ME, 20% of AdCA, 20% of MU, and 12.5% of WA cases as positive for over-expression of at least one gene, and identifi ed all AdCC, BCA, and PLGA cases as negative for over-expression. The difference in detected cases with over-expression (i.e. sensitivity) among disease groups was statistically signifi cant (Fisher exact test value = 16.623, p = 0.012). Conclusions: Either PLAG1 and HMGA2 gene overexpression levels could be very useful diagnostic tools for challenging PAs to differentiate from basloid lesions but one should warranted cautions as it can be positive in myoepithelial carcinoma, salivary duct adenocarcinoma, mucoepidermoid carcinoma and in rare cases of warthins tumor.
Results: The more differentiated mSGC (ACC, AciCC, MyC, MASC) have significantly lower frequencies of GA, TP53 mutations, targetable GA and TMB than the lessdifferentiated mSG (MEC, DCA, AC-NOS, CA-NOS, CPA). The less-differentiated CA are frequently ERBB2 driven tumors, but also harbor RET, BRAF and NF1 targets and feature higher TMB that will be shown to be responsive selected precision therapies. Background: Perineural invasion, histological (invasion; PNI) or radiologic (spread; PNS), an independent prognostic factor in head and neck carcinoma (HNCA), has been described as a feature to discriminate salivary gland extranodal marginal zone lymphoma (ENMZL) from benign lesions (LESA). Rare case reports of PNI/PNS in head and neck lymphomas (HNL) exist but no systematic studies have assessed its frequency, distribution and clinical significance. Design: 67 HNL, 10 gland lymphoproliferations and 10 lymphomas with reported PNI (including 5 HNL) were studied. PNI was reviewed by 2 observers, defined as tumor involving >33% of extratumoral nerve circumference or with concentric lamination or intraneural infiltration of intratumoral nerves (Liebig et al, 2009) . Number & size of involved fibers, distance to main tumor, and angiotropism were recorded. Clinicalradiology findings were available in 69 cases. Chi-square and t-test statistics were used. Results: Lymphomas were of B (n=69) and T (n=8) lineage, from 32 men & 45 women with median age of 61 yr (26-88). Most common HNL were follicular (n=21), DLBCL (n=20), and ENMZL (n=13) from parotid (n=27), cervical lymph nodes (n=16), submandibular gland (n =11), and oropharynx (n=8). Of 53 lymphomas with identifiable nerve fibers, 30 (57%) had PNI (16 aggressive, 14 indolent); 3 (10%) had neurologic symptoms and 4 (17%) showed PNS. PNI (>3 fibers) was extensive in 23 (77%); 13 (43%) had both intra and extratumoral PNI, mostly in small (<1 mm) fibers (n=22, 73%); and 16 (53%) showed angiotropism. 10 (42%) had recurrences, 7 locoregionally, none involving CNS. In lymphomas without PNI (n=23) (11 aggressive, 12 indolent), 6 (30%) recurred, 2 (10%) loco-regionally, but none had neurologic symptoms or PNS. Only 5 (22%) showed angiotropism. Among cases without nerve fibers (n=24), 2 (8%) had neurologic symptoms and 3 (12%) PNS. No benign lesions showed PNI, angiotropism, neurologic symptoms or PNS. No significant difference in demographic/clinical characteristics was found between PNI+ and PNI-HNL, but the PNI+ group showed a trend for locoregional recurrence (p=0.08) and a significant correlation with angiotropism (p<0.05). PNI was detected in 21/67 (31%) HNL at rereview but documented only in 5/72 (7%) HNL reports. Conclusions: PNI is a common, underreported finding in HNL, difficult to diagnose due to diffuse disease and ill-defined borders, requiring stricter criteria than in HNCA. It associates with angiotropism and is not seen in benign conditions. PNI in HNL may represent a locoregional spread pathway and should be reported. Whether it reflects true neurotropism is unclear. Laveniya Satgunaseelan, Hyerim Suh, Sohaib Virk, Bruce Ashford, Trina Lum, Marie Ranson, Jonathan Clark, Ruta Gupta. Royal Background: Metastatic squamous cell carcinoma of unknown primary is a common presentation in the neck. p16 expression, as determined by immunohistochemistry, is often used as a surrogate marker of human papillomavirus infection and an indicator of an oropharyngeal primary. Australia has the highest rate of cutaneous SCC (cSCC) in the world, with head and neck cSCC (HNcSCC) being known to present with cervical metastases. p16 expression in HNcSCC is yet to be elucidated. The objective of the study was to evaluate the incidence of p16 expression in HNcSCC and analyse its association with conventional prognostic factors and survival outcomes. Design: p16 immunohistochemistry was performed on tissue micro-arrays of 166 patients in the Sydney Head and Neck Cancer Institute database with HNcSCC (2000 HNcSCC ( -2013 and on whole sections (n=51) following histopathology review. Results: 53 (31.9%) cases showed strong, diffuse nuclear and cytoplasmic p16 expression. p16 expression significantly increased with increasing histological grade (p=0.005). No significant difference was seen in the rate of nodal involvement (p16 positive -73.1% vs. p16 negative -81.7%, p=0.21), extranodal spread (p16 positive -22.6% vs. p16 negative -26.5%, p=0.59), or other conventional histopathological parameters. p16 expression was not associated with disease-specific or disease-free survival. Conclusions: p16 expression is seen in nearly 32% of HN </del>cSCCs, particularly poorly differentiated HNcSCC. Thus HNcSCC should also be considered during the evaluation of squamous cell carcinoma of unknown primary in the neck, particularly in the regions with high prevalence of HNcSCC.
p16 Expression in Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck
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Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced versus Constitutional PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma Theresa Scognamiglio, Yao-Tseng Chen. Weill Cornell Medical College, New York, NY. Background: Immune checkpoint blockade with anti-PD1 antibody has been FDAapproved for treating metastatic head and neck squamous cell carcinoma (HNSCC) and an objective response rate of 18-20% has been reported. Defining PD-L1 expression at >1% tumor cells as positive, PD-L1-positive tumors showed higher response rate, suggesting PD-L1 as a predictive marker. However, it is unclear whether 1% is the optimal cutoff, and studies on lung cancer have suggested 50% cutoff as a stronger predictor of clinical response. Studies to correlate PD-L1 expression to HPV status were inconclusive, and correlations between primary and metastatic lesions have not been done. Design: 95 primary HNSCC from oropharynx and oral cavity were typed for membranous PD-L1 expression. 34 corresponding metastatic lesions were also tested. HPV status was determined by in situ hybridization or p16 as a surrogate marker. Results: 29 of 95 (31%) showed no PD-L1 expression. 35 (37%) showed induced expression at the tumor-immunocyte interface, either in immunocytes--lymphocytes and histiocytes--only (N=12) or in immunocytes and adjacent tumor cells (N=23). The remaining 31 (33%) showed constitutional expression in tumor cells beyond interface, including 21 in 5-50% of tumor cells and 10 (11% of all cases) in >50% of tumor cells (Figure 1 ).
Of the 34 primary-metastasis tumor pairs, PD-L1 expression was concordant in only 18 pairs (53%), whereas 8 cases each showed an up or down PD-L1 expression in metastasis. Most of these differences reflected changes in the induced expression, but not the constitutional expression. Among HPV(+) cases, 54% (22/41) showed induced PD-L1 expression, significantly more frequent than in the HPV(-) cases (13/54, 24%, p=0.03), likely reflecting their stronger immunogenicity. In contrast, both HPV(+) and HPV(-) had similar frequency of constitutional PD-L1 expression (34% vs. 32%). Conclusions: HNSCC could show constitutional PD-L1 expression or be induced to express PD-L1 at the tumor-immunocyte interface. Distinguishing these two patterns of expression and typing metastatic lesions before treatment might better predict clinical response to anti-PD1 (or anti-PD-L1) beyond the percentage of PD-L1-positive tumor cells.
(P-positive; S-strong; D-diffuse; F-focal; C-cytoplasmic; N-nuclear; W-weak; T-dot; M-membrane) Molecular studies showed FOXO1 translocations (n=9); PCR pending. Patients presented with high stage (IV: 22; III: 14) and metastatic disease (n=33). Surgery (n=11), radiation (n=30) and chemotherapy (n=33) yielded an overall survival of 40.5 mo (mean 2.4-286); 22 have disease (mean 17.3); 15 alive without disease (mean 72.9); 6 alive with disease (mean 8.8); 1 dead without disease (63.7); 16 dead with disease (mean 20.5). Conclusions: SNT ARMS frequently present in adults as a large, destructive midline mass of short symptom duration, with high stage disease. The alveolar to solid pattern of growth of cells with rhabdoid-plasmacytoid cells supports the diagnosis. Epithelial and neuroendocrine markers are frequently present, leading to misdiagnosis if muscle markers are not performed. Overall survival of 40.5 mo is achieved with multimodality therapy, but 56% have incurable disease (17.3 mo).
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Circulating Cell Free DNA Levels in Oral Squamous Cell Carcinoma Vandana Tiwari, Sudaiv Nagzarkar, Abhinav A Sonkar, Swati Kumari, Nuzhat Husain. Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh, India; King George's Medical University, Lucknow, Uttar Pradesh, India. Background: Oral squamous cell carcinoma (OSCC) represents the sixth prevalent malignancy worldwide and the third most common cancer in developing countries (1, 2). Estimation of Circulating free DNA may serve as non-invasive biomarker for detection of OSCC in an early stage. The present study was designed to assess serum cfDNA level in OSCC as compared to normal control. Design: Serum sample was collected from 44 patients with OSCC (Stage I=4, II=16, III=15, IV=9) and 20 healthy individuals. DNA was isolated by commercially available Kit. CfDNA levels were quantified by quantitative SYBR Green real-time PCR through amplification of β-globin gene. Results: Mean (±SD) cfDNA level was significantly higher in OSCC cases (317.42±392.47; range 10.508 -1566.28 ) as compared to normal controls (68.12±64.17; range 8.75 -218.55 p=0.004).Serum cfDNA levels were significantly associated with TNM stage III and IV patients and lymph node involvement (p= 0.004 & 0.0001 respectively). However, cfDNA levels did not correlate with histological grade of the patients. Association of cfDNA level with demographic and clinicopathological characterstics of the patients is summarized in Table 1 .
